Global Human Respiratory Syncytial Virus Drugs Market 2016-2020

Table of Contents

PART 01: Executive summary

• Highlights

PART 02: Scope of the report

• Market overview
• Top-vendor offerings

PART 03: Market research methodology

• Research methodology
• Economic indicators

PART 04: Introduction

• Key market highlights

PART 05: Disease overview

• Understanding the disease
• Symptoms
• Causes
• Risk factors
• Complications
• Tests and diagnosis
• Key buying criteria

PART 06: Pipeline analysis

PART 07: Market landscape

• Global respiratory syncytial virus drugs market
• Five forces analysis

PART 08: Market segmentation by category of drug

• Approved Drugs
• Off-label drugs

PART 09: Geographical segmentation

Human respiratory syncytial virus drugs market in US

• Human respiratory syncytial virus drugs market in Europe
• Human respiratory syncytial virus drugs market in ROW

PART 10: Market drivers

• Presence of large patient pool fuels market growth
• Launch of novel products
• Novel diagnostic tools increase patient population

PART 11: Impact of drivers

PART 12: Market challenges

• Continuous change in guidelines from healthcare organizations impacts market growth
• Cyclical nature of market hinders growth opportunities
• Limited drugs in market leading to low penetration rates

PART 13: Impact of drivers and challenges

PART 14: Market trends

• Emergence of new entrants likely to change market dynamics
• Growing strategic collaborations fostering innovation
• Active participation from emerging economies toward R&D

PART 15: Vendor landscape

• Competitive scenario

PART 16: Key vendor analysis

• AstraZeneca
• AbbVie
• GSK
• Teva Pharmaceutical
• Other prominent vendors

PART 17: Appendix

• List of abbreviations

PART 18: Explore Technavio